Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2016-08-24

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-16-0364PMID 27559142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

  2016cited by this paper
• High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates

  2015cited by this paper
• Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies

  2015cited by this paper
• HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

  2014cited by this paper
• A simple, robust and highly efficient transient expression system for producing antibodies.

  2014cited by this paper
• Controlled Fab-arm exchange for the generation of stable bispecific IgG1

  2014cited by this paper
• Antibody-drug conjugates: current status and future directions.

  2014cited by this paper
• HER2-directed therapy for metastatic breast cancer.

  2013cited by this paper
• Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

  2013cited by this paper
• Regulation of integrin function and trafficking

  2013cited by this paper
• Tetraspanin CD63 Promotes Vascular Endothelial Growth Factor Receptor 2-β1 Integrin Complex Formation, Thereby Regulating Activation and Downstream Signaling in Endothelial Cells in Vitro and in Vivo*

  2013cited by this paper
• Developments in the use of antibody-drug conjugates.

  2013cited by this paper
• GPI Transamidase and GPI anchored proteins: Oncogenes and biomarkers for cancer

  2013cited by this paper
• A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

  2013cited by this paper
• Distinct Recycling of Active and Inactive β1 Integrins

  2012cited by this paper
• Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9*

  2012cited by this paper
• Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

  2011cited by this paper
• Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases

  2010cited by this paper
• Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization

  2010cited by this paper
• Trafficking and function of the tetraspanin CD63.

  2009influential reference
• Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.

  2008cited by this paper
• Integrin traffic

  2006influential reference
• Mapping of tetraspanin-enriched microdomains that can function as gateways for HIV-1

  2006cited by this paper
• Role of the endocytic machinery in the sorting of lysosome-associated membrane proteins.

  2005cited by this paper
• Development of potent monoclonal antibody auristatin conjugates for cancer therapy

  2003cited by this paper
• Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.

  2003cited by this paper
• Tetraspanin CD63 promotes targeting and lysosomal proteolysis of membrane-type 1 matrix metalloproteinase.

  2003cited by this paper
• Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors

  2003cited by this paper
• The tetraspanin CD63 enhances the internalization of the H,K-ATPase beta-subunit.

  2003influential reference
• The tetraspanin CD63 enhances the internalization of the H,K-ATPase β-subunit

  2003cited by this paper
• Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2

  2002cited by this paper
• Recycling of the Cell Adhesion Molecule L1 in Axonal Growth Cones

  2000influential reference
• Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

  2000influential reference
• All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*)

  1996influential reference
• Protection against HIV‐1 infection in hu‐PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4‐binding site

  1995cited by this paper
• Biochemical and immunohistochemical characteristics of CD62 and CD63 monoclonal antibodies

  1992cited by this paper
• pH and the recycling of transferrin during receptor-mediated endocytosis.

  1983influential reference

• A cytokine receptor–targeting chimera toolbox for expanding extracellular targeted protein degradation

  2026cites this paper
• Antibody-drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology.

  2026cites this paper
• Bispecific antibody–drug conjugates: a modular blueprint for next-generation cancer therapeutics

  2026cites this paper
• Multi-specific antibody drug conjugate: The next frontier for solid tumors

  2026cites this paper
• Recent advances in bispecific antibody-drug conjugates for breast cancer therapy

  2026cites this paper
• Antibody–Drug Conjugates in Hematological Malignancies: Current Landscape and Future Perspectives

  2026cites this paper
• Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma

  2025cites this paper
• Antibody-drug conjugates in lung cancer: current landscape and future perspectives.

  2025cites this paper
• Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies

  2025cites this paper
• Chemotherapeutic Drug—Antibody Conjugates (ChemoBodies): Recent Advances and Future Directions

  2025cites this paper
• Hijacking Extracellular Targeted Protein Degrader–Drug Conjugates for Enhanced Drug Delivery

  2025cites this paper
• Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy.

  2025cites this paper
• The pleiotropic roles of non-hormonal receptor basigin and regulatory microRNAs in breast cancer

  2025cites this paper
• Pyrrolobenzodiazepine dimers for chemotherapy and antibody-drug conjugate applications.

  2025cites this paper
• Theranostic antibody conjugates: A review of recent trends and applications in cancer.

  2025cites this paper
• Recent Research Advances in HER2-Positive Breast Cancer Concerning Targeted Therapy Drugs

  2025cites this paper
• AI-driven innovation in antibody-drug conjugate design

  2025cites this paper
• Low-density lipoprotein receptor-targeting chimeras for membrane protein degradation and enhanced drug delivery

  2025cites this paper
• Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody.

  2025cites this paper
• Novel treatment approaches utilizing antibody-drug conjugates in breast cancer

  2025cites this paper
• A novel anti-HER2/EGFR bispecific antibody–drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs

  2025cites this paper
• Antibody Drug Conjugates (ADCs): Shaping the Future of Precision Oncology.

  2025cites this paper
• Bispecific antibodies as powerful immunotherapeutic agents for urological cancers: Recent innovations based on preclinical and clinical evidence

  2025cites this paper
• Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment

  2024cites this paper
• A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificity

  2024cites this paper
• Resistance to antibody–drug conjugates: A review

  2024cites this paper
• Development and Characterization of a Lysosome-Targeting SLC3A2/PD-L1 Bispecific Antibody-Drug Conjugate for Enhanced Anti-Tumor Efficacy in Solid Tumors.

  2024cites this paper
• Antibody-drug conjugates: prospects for the next generation.

  2024cites this paper
• Targeting Tetraspanins at Cell Interfaces: Functional Modulation and Exosome‐Based Drug Delivery for Precise Disease Treatment

  2024cites this paper
• Bispecific antibody drug conjugates: Making 1+1>2

  2024cites this paper
• Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses

  2024cites this paper
• Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges

  2024cites this paper
• Therapeutic potential of cis-targeting bispecific antibodies.

  2024cites this paper
• Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies

  2024cites this paper
• Unlocking the potential of bispecific ADCs for targeted cancer therapy

  2024cites this paper
• The Evolving Paradigm of Antibody–Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases

  2024cites this paper
• 癌症治疗中新型抗体偶联药物的研究进展

  2024cites this paper
• Antibody-drug conjugates in solid tumors; new strategy for cancer therapy

  2024cites this paper
• A novel SLC3A2-targeting antibody-drug conjugate exerts potent antitumor efficacy in head and neck squamous cell cancer

  2024cites this paper
• A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer

  2024cites this paper
• Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice

  2024cites this paper
• Better safe than sorry: dual targeting antibodies for cancer immunotherapy

  2024cites this paper
• Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment

  2023cites this paper
• Antibody-drug conjugates in lung cancer: dawn of a new era?

  2023cites this paper
• Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

  2023cites this paper
• Antibody–drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry

  2023cites this paper
• Revisiting the Role of CD63 as Pro‐Tumorigenic or Anti‐Tumorigenic Tetraspanin in Cancers and its Theragnostic Implications

  2023cites this paper
• T-Cell Engagers in Solid Cancers—Current Landscape and Future Directions

  2023cites this paper
• Bispecific antibodies in cancer therapy: Target selection and regulatory requirements

  2023cites this paper
• Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.

  2023cites this paper
• Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.

  2023cites this paper
• Optimizing the safety of antibody–drug conjugates for patients with solid tumours

  2023cites this paper
• Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions

  2023cites this paper
• Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

  2023cites this paper
• Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

  2023cites this paper
• IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins

  2023cites this paper
• Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor

  2023cites this paper
• The target atlas for antibody-drug conjugates across solid cancers

  2023cites this paper
• Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions

  2023influential citation
• Development of antibody‐drug conjugates in cancer: Overview and prospects

  2023cites this paper
• The eIg technology to generate Ig-like bispecific antibodies

  2022cites this paper
• Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics

  2022cites this paper
• Antibody drug conjugate: the “biological missile” for targeted cancer therapy

  2022cites this paper
• Development of therapeutic antibodies for the treatment of diseases

  2022cites this paper
• Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

  2022cites this paper
• Drug conjugate-based anticancer therapy - Current status and perspectives.

  2022cites this paper
• More than Toxins-Current Prospects in Designing the Next Generation of Antibody Drug Conjugates.

  2022cites this paper
• Generating a Bispecific Antibody Drug Conjugate Targeting PRLR and HER2 with Improving the Internalization

  2022cites this paper
• Antibody-drug conjugates: beyond current approvals and potential future strategies

  2022cites this paper
• The Design and Development of Antibody–Drug Conjugates (ADC s ) for the Treatment of Cancer

  2021cites this paper
• The promise of bispecific antibodies: Clinical applications and challenges.

  2021cites this paper
• Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer

  2021cites this paper
• Bioassay Development for Bispecific Antibodies—Challenges and Opportunities

  2021cites this paper
• A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3

  2021cites this paper
• A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo

  2021cites this paper
• Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope.

  2021cites this paper
• Unlocking the potential of antibody–drug conjugates for cancer therapy

  2021cites this paper
• Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond

  2021cites this paper
• Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry

  2021cites this paper
• Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.

  2021cites this paper
• Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies

  2021cites this paper
• Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model

  2021cites this paper
• Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.

  2021cites this paper
• Introduction to Antibody Engineering

  2021influential citation
• Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

  2021cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy

  2020cites this paper
• Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2

  2020influential citation
• Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer.

  2020cites this paper
• Fine-tuning bispecific therapeutics.

  2020cites this paper
• Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

  2020cites this paper
• Protein labeling approach to improve lysosomal targeting and efficacy of antibody-drug conjugates.

  2020cites this paper
• A DNA-nanoassembly-based approach to map membrane protein nanoenvironments

  2020cites this paper
• An Overview of the Current ADC Discovery Landscape.

  2020cites this paper
• Bispecific Antibodies

  2020cites this paper
• Antibody‐drug conjugates‐ stability and formulation

  2019cites this paper
• Antibody-drug conjugates for lung cancer in the era of personalized oncology.

  2019cites this paper
• Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design

  2019cites this paper
• Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

  2019cites this paper
• Bispecific antibodies: a mechanistic review of the pipeline

  2019cites this paper